Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T66693
(Former ID: TTDR00934)
|
|||||
Target Name |
B-cell maturation protein (TNFRSF17)
|
|||||
Synonyms |
Tumor necrosis factor receptor superfamily member 17; CD269; BCMA; BCM
Click to Show/Hide
|
|||||
Gene Name |
TNFRSF17
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Multiple myeloma [ICD-11: 2A83] | |||||
Function |
Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL.
Click to Show/Hide
|
|||||
UniProt ID | ||||||
Sequence |
MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCL
GLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLE YTVEECTCEDCIKSKPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKS ISAR Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
1 | Idecabtagene vicleucel | Drug Info | Approved | Multiple myeloma | [4] | |
2 | Teclistamab | Drug Info | Approved | Multiple myeloma | [5] | |
Clinical Trial Drug(s) | [+] 33 Clinical Trial Drugs | + | ||||
1 | Bb2121 | Drug Info | Phase 2 | Multiple myeloma | [9], [10] | |
2 | LCAR-B38M CAR-T Cell | Drug Info | Phase 2 | Multiple myeloma | [1], [11] | |
3 | Anti-BCMA CAR-T cells | Drug Info | Phase 1/2 | Multiple myeloma | [15] | |
4 | Anti-BCMA-CAR-transduced T cells | Drug Info | Phase 1/2 | leukaemia | [16] | |
5 | AUTO2 | Drug Info | Phase 1/2 | Multiple myeloma | [17] | |
6 | BCMA CAR T cells | Drug Info | Phase 1/2 | Multiple myeloma | [18] | |
7 | BCMA CAR-T | Drug Info | Phase 1/2 | Multiple myeloma | [19] | |
8 | CAR-T cells targeting BCMA | Drug Info | Phase 1/2 | leukaemia | [20] | |
9 | CART-19/BCMA | Drug Info | Phase 1/2 | Multiple myeloma | [21] | |
10 | CART-BCMA cells | Drug Info | Phase 1/2 | Multiple myeloma | [22] | |
11 | CD38 and BCMA CAR-T Cells | Drug Info | Phase 1/2 | Multiple myeloma | [23] | |
12 | JCARH125 | Drug Info | Phase 1/2 | Multiple myeloma | [24], [25] | |
13 | JNJ-68284528 | Drug Info | Phase 1/2 | Multiple myeloma | [26] | |
14 | Anti-BCMA CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [49] | |
15 | Anti-BCMA CAR-T cells | Drug Info | Phase 1 | leukaemia | [50] | |
16 | Anti-BCMA CART Cells | Drug Info | Phase 1 | Multiple myeloma | [51] | |
17 | Bb21217 | Drug Info | Phase 1 | Multiple myeloma | [52] | |
18 | BCMA CAR-T Cells | Drug Info | Phase 1 | Multiple myeloma | [53] | |
19 | BCMA CART | Drug Info | Phase 1 | Multiple myeloma | [54] | |
20 | BCMA CART and huCART19 | Drug Info | Phase 1 | Multiple myeloma | [54] | |
21 | BCMA nanobody CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [55] | |
22 | BCMA-specific CAR-expressing T Lymphocytes | Drug Info | Phase 1 | Plasma cell myeloma | [56] | |
23 | C-CAR088 | Drug Info | Phase 1 | Multiple myeloma | [57] | |
24 | CAR-T cells targeting BCMA | Drug Info | Phase 1 | Multiple myeloma | [58] | |
25 | CART-BCMA | Drug Info | Phase 1 | Multiple myeloma | [59] | |
26 | IM21 CART | Drug Info | Phase 1 | Multiple myeloma | [60] | |
27 | KITE-585 | Drug Info | Phase 1 | Multiple myeloma | [9] | |
28 | LCAR-B4822M CAR-T Cell | Drug Info | Phase 1 | Multiple myeloma | [61] | |
29 | P-BCMA-101 CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [62] | |
30 | BCMA-CART | Drug Info | Clinical trial | Multiple myeloma | [63] | |
31 | BCMA-UCART | Drug Info | Clinical trial | Multiple myeloma | [64] | |
32 | CAR-BCMA T cell | Drug Info | Clinical trial | Multiple myeloma | [65] | |
33 | CAR-T cells targeting BCMA | Drug Info | Clinical trial | Multiple myeloma | [66] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
CAR-T-Cell-Therapy | [+] 29 CAR-T-Cell-Therapy drugs | + | ||||
1 | Idecabtagene vicleucel | Drug Info | [4] | |||
2 | LCAR-B38M CAR-T Cell | Drug Info | [1], [11] | |||
3 | Anti-BCMA CAR-T cells | Drug Info | [15] | |||
4 | Anti-BCMA-CAR-transduced T cells | Drug Info | [16] | |||
5 | BCMA CAR T cells | Drug Info | [18] | |||
6 | BCMA CAR-T | Drug Info | [19] | |||
7 | CAR-T cells targeting BCMA | Drug Info | [20] | |||
8 | CART-BCMA cells | Drug Info | [22] | |||
9 | JCARH125 | Drug Info | [24], [25] | |||
10 | JNJ-68284528 | Drug Info | [26] | |||
11 | Anti-BCMA CAR-T cells | Drug Info | [49] | |||
12 | Anti-BCMA CAR-T cells | Drug Info | [50] | |||
13 | Anti-BCMA CART Cells | Drug Info | [51] | |||
14 | Bb21217 | Drug Info | [52] | |||
15 | BCMA CAR-T Cells | Drug Info | [53] | |||
16 | BCMA CART | Drug Info | [54] | |||
17 | BCMA nanobody CAR-T cells | Drug Info | [55] | |||
18 | BCMA-specific CAR-expressing T Lymphocytes | Drug Info | [56] | |||
19 | C-CAR088 | Drug Info | [57] | |||
20 | CAR-T cells targeting BCMA | Drug Info | [58] | |||
21 | CART-BCMA | Drug Info | [59] | |||
22 | IM21 CART | Drug Info | [60] | |||
23 | KITE-585 | Drug Info | [68] | |||
24 | LCAR-B4822M CAR-T Cell | Drug Info | [61] | |||
25 | P-BCMA-101 CAR-T cells | Drug Info | [62] | |||
26 | BCMA-CART | Drug Info | [63] | |||
27 | BCMA-UCART | Drug Info | [64] | |||
28 | CAR-BCMA T cell | Drug Info | [65] | |||
29 | CAR-T cells targeting BCMA | Drug Info | [66] | |||
Immunomodulator | [+] 1 Immunomodulator drugs | + | ||||
1 | Bb2121 | Drug Info | [10] | |||
CAR-T-Cell-Therapy(Dual specific) | [+] 4 CAR-T-Cell-Therapy(Dual specific) drugs | + | ||||
1 | AUTO2 | Drug Info | [17] | |||
2 | CART-19/BCMA | Drug Info | [21] | |||
3 | CD38 and BCMA CAR-T Cells | Drug Info | [23] | |||
4 | BCMA CART and huCART19 | Drug Info | [54] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Cytokine-cytokine receptor interaction | hsa04060 | Affiliated Target |
|
Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
Intestinal immune network for IgA production | hsa04672 | Affiliated Target |
|
Class: Organismal Systems => Immune system | Pathway Hierarchy |
Degree | 5 | Degree centrality | 5.37E-04 | Betweenness centrality | 1.75E-05 |
---|---|---|---|---|---|
Closeness centrality | 1.89E-01 | Radiality | 1.32E+01 | Clustering coefficient | 6.00E-01 |
Neighborhood connectivity | 1.20E+01 | Topological coefficient | 2.61E-01 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-interacting Proteins |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | |||||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||||
REF 3 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345 | |||||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. | |||||
REF 5 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291. | |||||
REF 6 | ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health. | |||||
REF 7 | ClinicalTrials.gov (NCT04816526) Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health. | |||||
REF 8 | ClinicalTrials.gov (NCT04436029) Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health. | |||||
REF 9 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 10 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 11 | ClinicalTrials.gov (NCT03090659) LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | |||||
REF 12 | ClinicalTrials.gov (NCT04171843) A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 13 | ClinicalTrials.gov (NCT04083534) First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM). U.S. National Institutes of Health. | |||||
REF 14 | ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 15 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | |||||
REF 16 | ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | |||||
REF 17 | ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma | |||||
REF 18 | ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | |||||
REF 19 | ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma | |||||
REF 20 | ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | |||||
REF 21 | ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT | |||||
REF 22 | ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma | |||||
REF 23 | ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | |||||
REF 24 | ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | |||||
REF 25 | ClinicalTrials.gov (NCT03430011) Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma | |||||
REF 26 | ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | |||||
REF 27 | ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma | |||||
REF 28 | ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | |||||
REF 29 | ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | |||||
REF 30 | ClinicalTrials.gov (NCT03602612) T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | |||||
REF 31 | ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma | |||||
REF 32 | Clinical pipeline report, company report or official report of Arcellx. | |||||
REF 33 | ClinicalTrials.gov (NCT04093596) Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). U.S. National Institutes of Health. | |||||
REF 34 | ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health. | |||||
REF 35 | ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 36 | ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 37 | ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 38 | ClinicalTrials.gov (NCT04184050) A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM. U.S. National Institutes of Health. | |||||
REF 39 | ClinicalTrials.gov (NCT04244656) A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 40 | ClinicalTrials.gov (NCT04249947) P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health. | |||||
REF 41 | ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health. | |||||
REF 42 | ClinicalTrials.gov (NCT04434469) A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 43 | ClinicalTrials.gov (NCT04162353) BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma. U.S. National Institutes of Health. | |||||
REF 44 | ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health. | |||||
REF 45 | ClinicalTrials.gov (NCT03933735) A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 46 | ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health. | |||||
REF 47 | Clinical pipeline report, company report or official report of Roche | |||||
REF 48 | ClinicalTrials.gov (NCT03582033) A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health. | |||||
REF 49 | ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | |||||
REF 50 | ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies | |||||
REF 51 | ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | |||||
REF 52 | ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma | |||||
REF 53 | ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma | |||||
REF 54 | ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma | |||||
REF 55 | ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma | |||||
REF 56 | ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma | |||||
REF 57 | ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | |||||
REF 58 | ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | |||||
REF 59 | ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma | |||||
REF 60 | ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | |||||
REF 61 | ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | |||||
REF 62 | ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) | |||||
REF 63 | ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | |||||
REF 64 | ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART | |||||
REF 65 | ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | |||||
REF 66 | ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma | |||||
REF 67 | Clinical pipeline report, company report or official report of Poseida Therapeutics. | |||||
REF 68 | ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.